Health & Life Co., Ltd. AI Stock Analysis
Health & Life Co., Ltd. (1781) AI Stock Analysis
Health & Life Co., Ltd.
(TPEx:1781)
The score is driven primarily by weak profitability and cash generation, reinforced by a bearish position below all listed moving averages and negative MACD. Oversold momentum indicators provide only limited support, while the negative P/E offers no valuation cushion.
Health & Life Co., Ltd. (1781) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 407.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 44.63K
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 0.43
- Revenue Growth
- -12.12%
- EPS Growth
- -17.29%
- Country
- TW
- Employees
- 120
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Health & Life Co., Ltd. Business Overview & Revenue Model
Company Description
Health & Life Co., Ltd. is a global provider of medical devices. Established in 1996 and headquartered in New Taipei City, Taiwan, the company specializes in developing and distributing solutions for critical health sectors, including cardiovascular...
Health & Life Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak: revenue declined 9.9%, the company reported a net loss, margins were negative, free cash flow was negative, and operating cash flow was minimal. Positive equity and manageable leverage provide limited support, but the underlying financial scores average below the required minimum and are therefore floored at 37.
Income Statement
18Very NegativeBalance Sheet
63PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 400.09M | 398.05M | 706.39M | 601.17M | 797.54M | 811.88M |
| Gross Profit | 52.62M | 70.12M | 147.74M | 93.11M | 97.72M | 45.76M |
| EBITDA | -31.11M | -46.70M | 55.63M | -7.84M | 11.85M | -63.05M |
| Net Income | -50.67M | -61.67M | 24.24M | -33.23M | -17.55M | -62.34M |
Balance Sheet | ||||||
| Total Assets | 655.77M | 723.13M | 817.26M | 710.79M | 799.76M | 776.39M |
| Cash, Cash Equivalents and Short-Term Investments | 222.42M | 247.94M | 277.35M | 151.05M | 156.98M | 200.32M |
| Total Debt | 198.03M | 196.97M | 214.14M | 113.60M | 189.45M | 134.81M |
| Total Liabilities | 352.54M | 402.56M | 424.21M | 375.42M | 427.18M | 398.22M |
| Stockholders Equity | 303.23M | 320.57M | 393.05M | 335.37M | 372.58M | 378.18M |
Cash Flow | ||||||
| Free Cash Flow | -25.33M | -5.01M | 30.14M | 76.82M | -93.02M | -145.04M |
| Operating Cash Flow | -16.54M | 3.18M | 33.35M | 84.91M | -80.69M | -131.15M |
| Investing Cash Flow | 41.19M | 41.96M | -89.81M | -8.78M | -10.32M | -16.02M |
| Financing Cash Flow | -15.78M | -21.91M | 128.68M | -74.67M | 25.91M | -91.10M |
Health & Life Co., Ltd. Peers Comparison
Overall Rating
- TW:178139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:1781 | 39Underperform | TWD 407.71M | -8.04 | ― | ― | -12.12% | -17.29% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1781 | Health & Life Co., Ltd. | 8.60 | -3.40 | -28.33% | |
| TW:4115 | Sunder Biomedical Tech. Co., Ltd. | 6.97 | -1.23 | -15.00% | |
| TW:4117 | General Biologicals Corp. | 7.41 | -4.79 | -39.26% | |
| TW:4186 | Taiwan Advance Bio-Pharmaceutical, Inc. | 7.00 | -5.95 | -45.95% | |
| TW:6549 | TaiwanJ Pharmaceuticals Co., Ltd. | 6.25 | -1.61 | -20.48% | |
| TW:6621 | Unipharma Co., Ltd. | 12.00 | -0.20 | -1.64% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026